Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2025-04-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2025 年第一季度报告' which translates to '2025 First Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and explanations of financial changes for the first quarter of 2025. It explicitly states it is a quarterly report and includes comprehensive financial statements and analysis. The document length is over 12,000 characters, indicating it is a full report rather than a brief announcement. It also states the report is unaudited, which is typical for interim/quarterly reports. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-25 Chinese
关于召开2024年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2024 Annual General Meeting (AGM) of 美康生物科技股份有限公司, including the date, time, venue, voting procedures (both in-person and online), agenda items to be discussed and voted on, and attachments such as proxy forms and shareholder registration forms. It does not contain financial statements or management discussion and analysis but rather focuses on informing shareholders about the AGM logistics and agenda. The document length is about 6307 characters, which is consistent with a detailed meeting notice rather than a full annual report or financial report. Therefore, this document fits the category of AGM Information (AGM-R).
2025-04-18 Chinese
2024年度财务决算报告
Annual Report Classification · 100% confidence The document is titled as the 2024年度财务决算报告 (2024 Annual Financial Settlement Report) of 美康生物科技股份有限公司. It contains detailed financial statements including income statement, balance sheet, cash flow statement, and notes on significant changes in financial items. It also mentions that the financial statements have been audited by a certified accounting firm with an unqualified opinion. The document length is 7261 characters, which is substantial and contains actual financial data and analysis for the full fiscal year 2024. This matches the definition of an Annual Report (10-K) which covers the company's full financial performance for the year. There is no indication that this is merely an announcement or a certification letter, and it is not a quarterly or interim report. Therefore, the correct classification is Annual Report (10-K). FY 2024
2025-04-18 Chinese
2024年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2024年度监事会工作报告" which translates to the "2024 Supervisory Board Work Report" of the company. It details the supervisory board's activities, meetings, oversight on financials, internal controls, related party transactions, and plans for 2025. It includes audit opinions and supervisory conclusions but is not a full annual report or audit report by itself. The document is a formal report from the supervisory board summarizing their oversight work and opinions for the year 2024. This fits the category of a Management Report (MDA), which includes management's detailed explanation of financial results, business trends, and outlook. The document is 4169 characters long, which is substantive and contains detailed supervisory content rather than just an announcement or certification. Therefore, the best classification is Management Reports (MDA).
2025-04-18 Chinese
2024年度非经营性资金占用及其他关联资金往来情况的专项报告
Audit Report / Information Classification · 95% confidence The document is a specialized report titled '专项报告' (Special Report) concerning non-operating fund occupation and other related party fund transactions for the fiscal year 2024. It references audited financial statements for the year ending December 31, 2024, and includes detailed tables summarizing related party transactions and fund usage. The report is prepared in accordance with regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange self-regulatory guidelines. The document is about 4220 characters long, which is relatively short and focused on a specific topic rather than a full annual report or interim report. It is not a general annual report (10-K), nor an earnings release or management discussion. It is a standalone audit-related report focusing on a specific regulatory compliance area related to funds and related party transactions, which fits the definition of an Audit Report / Information (AR). FY 2024
2025-04-18 Chinese
2024年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2024年度募集资金存放与使用情况的专项报告" which translates to "2024 Annual Special Report on the Deposit and Use of Raised Funds." It details the amount of funds raised, their storage, usage, and management according to regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The report includes detailed tables on the use of raised funds, project progress, and compliance with regulations. It is a specialized report focused on the management and use of capital raised by the company, not a general financial report or earnings release. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is over 10,000 characters, contains substantive financial and operational data related to fundraising, and is not merely an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2025-04-18 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.